Ambassadors Group Inc. (NASDAQ:EPAX) announced its results for the fourth quarter and full year ended December 31, 2014. Gross revenue from continuing operations, including non-directly delivered programs, of $99.5 million during 2014 compared to $112.2 million in the prior year. During 2014, the Company traveled 16,092 delegates compared to 18,251 delegates in the same period in 2013. On Wednesday shares of Ambassadors Group Inc. (NASDAQ:EPAX) closed at $2.40. Company’s sales growth for last 5 years was -12.20% and EPS growth for next 5 years is recorded as 15.00%.
On 9 February, Atossa Genetics, Inc. (NASDAQ:ATOS) said that it has signed an agreement with Thermo Fisher Scientific for distribution of Atossa’s FullCYTE Breast Aspirator device in the United States through the Fisher HealthCare channel. Atossa’s FullCYTE Breast Aspirator is used by physicians and nurses to collect nipple aspirate fluid from a patient’s breasts for cytological analysis. Atossa Genetics, Inc. (NASDAQ:ATOS) in last trading activity fell -1.40% to close at $1.41. Company weekly performance is 17.99% while its quarterly performance stands at 36.89%. Atossa Genetics, Inc. (NASDAQ:ATOS) is -45.14% away from its 52 week high.
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) announced that the company will host a conference call and live webcast on Tuesday, February 17, 2015 at 8:30 a.m. EST to report its fourth quarter and full year 2014 financial results and discuss recent business activities. On last trading day Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) fell -0.69% to close at $116.20. Its volatility for the week is 7.23% while volatility for the month is 6.93%. Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) monthly performance is -11.67%.
On 29 January, Bristol-Myers Squibb Company (NYSE:BMY) announced that the US Food and Drug Administration (FDA) has approved its drug Evotaz as a fixed-dose combination of atazanavir, cobicistat, and other antiretroviral agents to treat adult patients with human immunodeficiency virus (HIV-1). On Wednesday shares of Bristol-Myers Squibb Company (NYSE:BMY) closed at $59.31. Company’s sales growth for last 5 years was -3.30% and EPS growth for next 5 years is recorded as 15.64%.
TransAct Technologies Incorporated (NASDAQ:TACT) announced that its Board of Directors has declared a quarterly cash dividend of $0.08 per share. The dividend will be payable on March 13, 2015, to shareholders of record at the close of business on February 20, 2015. On last trading day TransAct Technologies Incorporated (NASDAQ:TACT) moved up 2.94% to close at $6.30. Its volatility for the week is 4.58% while volatility for the month is 3.70%. TACT’s sales growth for past 5 years was -0.70% and its EPS growth for past 5 years was 30.60%. TransAct Technologies Incorporated (NASDAQ:TACT) monthly performance is 4.13%.